What’s News in Earnings: How Big Pharma Is Expanding the GLP-1 Market

About this episode

The episode discusses the financial results of major pharmaceutical companies and their competition in the GLP-1 market for weight-loss and autoimmune drugs.

Bonus Episode for May 8. Financial results from pharmaceutical companies Eli Lilly, Novo Nordisk, Merck, Bristol Myers Squibb and AbbVie show strong demand continuing for weight-loss drugs and autoimmune treatments. Wall Street Journal pharma reporter Peter Loftus discusses which drugmakers have the upper hand in the race to dominate those markets. WSJ Heard on the Street columnist David Wainer hosts this special bonus episode of What's News in Earnings, where we dig into companies’ earnings reports and analyst calls to find out what’s going on under the hood of the American economy. Sign up for the WSJ's free Markets A.M. newsletter. Learn more about your ad choices. Visit megaphone.fm/adchoices

People in this episode

Host: David Wainer

Guest: Peter Loftus

Topics covered

• pharmaceutical earnings
• weight-loss drugs
• autoimmune treatments
• market competition
• financial results

Keywords

• pharmaceutical companies
• Eli Lilly
• Novo Nordisk
• weight-loss drugs
• autoimmune treatments
• earnings reports
• Wall Street Journal

Mentioned in this episode

Organizations: Eli Lilly, Novo Nordisk, Merck, Bristol Myers Squibb, AbbVie

More episodes of WSJ What’s News

• SpaceX Is Now America’s 6th Most Valuable Public Company · June 12, 2026 · 13 min
• Will SpaceX Skyrocket on Trading Debut? · June 12, 2026 · 16 min
• Stocks Soar After Trump Cancels Threatened Strikes on Iran · June 11, 2026 · 12 min
• Why OpenAI Might Slash Prices for Users · June 11, 2026 · 15 min
• Elon Musk Is Betting Big on Retail Investors With SpaceX’s IPO · June 10, 2026 · 14 min
• Can Regulators Get a Grip on Prediction Markets? · June 10, 2026 · 12 min